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tion (Cryo-AF) using the newly available third-generation (Arctic
Front Advance-Short Tip [AFA-ST]) cryoballoon.
OBJECTIVE In this multicenter study, we evaluated the safety and
efﬁcacy of Cryo-AF using the AFA-ST vs the second-generation
(Arctic Front Advance [AFA]) cryoballoon.
METHODS We examined the procedural safety and efﬁcacy and the
short- and long-term clinical outcomes associated with a ﬁrst-time
Cryo-AF performed in 355 consecutive patients (254/355 [72%]
with paroxysmal AF), using either the AFA-ST (n = 102) or the AFA
(n = 253) cryoballoon catheters.
RESULTS Acute isolation was achieved in 99.6% of all pulmonary veins
(PVs) (AFA-ST: 100% vs AFA: 99.4%; P¼ .920). Time to pulmonary vein
isolation was recorded in 89.2% of PVs using AFA-ST vs 60.2% using AFA
(Po .001). PVs targeted using AFA-ST required fewer applications (1.6
± 0.8 vs 1.7 ± 0.8; P¼ .023), whereas there were no differences in the
balloon nadir temperature (AFA-ST: −47.0°C ± 7.3°C vs AFA: −47.5°C ±
7.8°C; P¼ .120) or thaw time (AFA-ST: 41± 24 seconds vs AFA: 44± 28
seconds; P ¼ .056). However, AFA-ST was associated with shorter leftDr Aryana, Dr Ellenbogen, Dr Kenigsberg, Dr Kowalski, and Dr O’Neill
have received consulting fees and speaker honoraria from Medtronic.
Dr Aryana and Dr O’Neill have received a research grant from Medtronic.
Dr Koo is a member of the Medtronic strategic advisory board. Dr Lim and
Mr Hokanson are employees of Medtronic. Address reprint requests and
correspondence: Dr Arash Aryana, Department of Cardiology and Cardi-
ovascular Surgery, Mercy General Hospital and Dignity Health Heart and
Vascular Institute, 3941 J St, Suite #350, Sacramento, CA 95819. E-mail
address: a_aryana@outlook.com.
1547-5271/$-see front matter B 2016 The Authors. Published by Elsevier Inc. on
10.1016/j.hrthm.2016.08.011atrial dwell time (43 ± 5 minutes vs 53 ± 16 minutes; Po .001) and
procedure time (71 ± 11 minutes vs 89 ± 25 minutes; P o .001).
Furthermore, Cryo-AF using AFA-ST was completed more frequently by
“single-shot” PV ablation (27.4% vs 20.2%; P ¼ .031). Persistent
phrenic nerve palsy (AFA-ST: 0% vs AFA: 0.8%; P ¼ .507) and
procedure-related adverse events (AFA-ST: 1.0% vs AFA: 1.6%; P ¼
.554) were similar, as was the freedom from recurrent atrial arrhythmias
at 10 months of follow-up (AFA-ST: 81.8% vs AFA: 79.9%; P ¼ .658).
CONCLUSION Cryo-AF using the AFA-ST cryoballoon offers an
enhanced ability to assess time to pulmonary vein isolation,
allowing for fewer cryoapplications and shorter left atrial dwell
time and procedure time. Consequently, this allowed for procedural
completion more frequently using a “single-shot” PV ablation with
equivalent safety and efﬁcacy.
KEYWORDS Catheter ablation; Atrial ﬁbrillation; Cryoablation;
Cryoballoon; Pulmonary vein isolation
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Contemporary studies of cryoablation of atrial ﬁbrillation
(Cryo-AF) using the second-generation cryoballoon (ArcticFront Advance [AFA] Medtronic, Inc., Minneapolis, MN)
have adopted shorter and fewer cryoapplications while still
demonstrating acceptable clinical outcomes.1–3 Although there
are presently no uniform guidelines on the optimal Cryo-AF
dosing, a greater emphasis has recently been placed on
directing this procedure through objective and quantiﬁable
procedural and biophysical markers.2 Several studies have
identiﬁed the time to pulmonary vein (PV) isolation (TT-PVI)
as an essential indicator of acute and durable PVI.4–7 Fur-
thermore, this has shown to reduce the requirement for the
number of cryoapplications as well as procedural duration and
ﬂuoroscopic utilization.8 However, TT-PVI cannot always bebehalf of Heart Rhythm Society. All rights reserved. http://dx.doi.org/
Figure 1 An illustration depicting the principal design change between the AFA and the AFA-ST cryoballoons. As shown, the length of the distal tip (L) of the
AFA-ST cryoballoon is ~40% shorter than that of the AFA balloon (8 mm vs 13 mm, respectively), thereby allowing farther withdrawal (d) of the inner lumen
circular mapping catheter through the inner lumen of the cryoballoon to a more proximal location within the pulmonary vein ostia. AFA¼Arctic Front Advance;
AFA-ST ¼ Arctic Front Advance-Short Tip.
2307Aryana et al Cryoablation of AF Using AFA vs AFA-STmeasured during Cryo-AF using the AFA cryoballoon.9 This is
at least in part related to the design of this catheter. That is, the
AFA catheter’s long distal tip can frequently impede sufﬁcient
withdrawal of the inner lumen circular mapping catheter
(Achieve, Medtronic, Inc.) to a proximal location in the PV
ostia where the muscular sleeves typically lie. Consequently,
this has led to the development of a third-generation cryobal-
loon (Arctic Front Advance-Short Tip [AFA-ST], Medtronic,
Inc.). Speciﬁcally, the 8-mm distal tip of the AFA-ST
cryoballoon is ~40% shorter than the 13-mm tip of the AFA.
Aside from its signiﬁcantly shorter distal tip, the design of this
novel balloon is overall remarkably similar to that of the AFA
catheter (Figure 1). However, there is little data on the safety
and efﬁcacy of Cryo-AF using the AFA-ST.
In this multicenter study using a nonrandomized, double-
arm, prospective design, we retrospectively analyzed the
the short- and long-term outcomes of Cryo-AF using the
AFA-ST vs the AFA cryoballoons in a large cohort of
patients with symptomatic paroxysmal and persistent atrial
ﬁbrillation (AF).
Methods
Study patients
The study cohort consisted of consecutive patients undergoing a
ﬁrst-time Cryo-AF for symptomatic paroxysmal/persistent AF
between March 1, 2015 and November 1, 2015. The procedures
were performed by 6 experienced operators at 5 centers. The
study sites included Mercy General Hospital (Sacramento, CA),
Staten Island University Hospital (Staten Island, NY), Jersey
Shore University Medical Center (Neptune, NJ), Westside
Regional Medical Center (Plantation, FL), and Broward Health
Medical Center (Fort Lauderdale, FL). Approval for this study
was granted by each facility’s institutional review board.
Procedural details
Brieﬂy, diagnostic electrophysiology catheters including
a coronary sinus decapolar and a right atrial quadripolarcatheter were positioned for recording and pacing, followed
by single transseptal catheterization. Intravenous heparin
was administered at the time of transseptal puncture followed
by an infusion (target activated clotting time ≥300 seconds).
All patients underwent PVI using a 23-mm or a 28-mm AFA
or AFA-ST cryoballoon catheter inserted through a 12-F
steerable sheath (FlexCath, Medtronic, Inc.) over a 20-mm
inner lumen circular mapping (Achieve) catheter. In the ﬁrst
phase of the study, all procedures were performed using the
AFA balloon. During the second phase, once the AFA-ST
balloon became commercially available, all the procedures
were then completed using the AFA-ST balloon. Balloon
size selection was guided by PV size/anatomy as determined
by preprocedural computed tomographic angiography, intra-
procedural left atrial (LA) angiography, or intraprocedural
intracardiac echocardiography. Optimal cryoballoon posi-
tioning was conﬁrmed by PV angiography. All operators
followed the same protocol for cryoablation. Attempts were
made to speciﬁcally record TT-PVI during ablation of each
PV, during each and every procedure. Based on the currently
available data, either 1 or 2 effective cryoapplications were
delivered to each PV, guided by TT-PVI. That is, a single
cryoapplication was delivered to a PV if TT-PVI measured
≤60 seconds, whereas a second cryoapplication was deliv-
ered if TT-PVI 460 seconds or simply could not be
measured. Those cryoapplications that did not achieve a
TT-PVI of ≤90 seconds were abandoned. PVI was con-
ﬁrmed by testing for entrance/exit block and after the
administration of intravenous adenosine. Luminal esophageal
temperature was monitored throughout ablation. Esophageal
temperatures o15°C were avoided. During cryoablation of
the right PVs, high-output right phrenic nerve (PN) stimula-
tion (10–25 mA; 1000–1200 ms) was performed using the
diagnostic quadripolar catheter from within the superior vena
cava. Whenever diminished or loss of pacing capture
was observed, cryoablation was immediately terminated.
PN palsy was classiﬁed as either transient or persistent.
Transient PN palsy was deﬁned as diminished/absence
Table 1 Baseline patient demographics and characteristics
Characteristic AFA (n ¼ 253) AFA-ST (n ¼ 102) P
Age (y) 64 ± 10 64 ± 11 .745
Sex: male 172 (68) 71 (70) .778
Body mass index (kg/m2) 30 ± 6 31 ± 6 .253
Hypertension 174 (69) 68 (67) .783
Diabetes mellitus 55 (22) 27 (26) .505
Dyslipidemia 139 (55) 61 (60) .449
Sleep apnea 70 (28) 35 (34) .288
Stroke/transient ischemic attack 26 (10) 16 (16) .221
LA diameter (mm) 43 ± 6 45 ± 6 .179
LA volume index (mL/m2) 39 ± 14 43 ± 10 .170
Left ventricular ejection fraction (%) 55 ± 10 56 ± 8 .198
Coronary artery disease 50 (20) 24 (24) .386
Myocardial infarction 27 (11) 2 (2) .002*
Percutaneous coronary intervention 34 (13) 10 (10) .366
Coronary artery bypass graft 22 (9) 14 (14) .075
Cardiac implantable electronic device 37 (15) 15 (15) .983
Paroxysmal AF 179 (71) 75 (74) .663
Prior cardioversion 173 (68) 80 (78) .071
No. of prior cardioversions per patient 1.0 ± 1.0 1.0 ± 0.8 .551
CHADS2 score 1.4 ± 1.0 1.7 ± 1.2 .113
No. of antiarrhythmic drugs per patient 1.2 ± 0.7 1.3 ± 0.7 .285
Antiplatelet therapy 23 (9) 5 (5) .139
Oral anticoagulation therapy 218 (86) 86 (84) .661
Vitamin K antagonist 38 (15) 10 (10) .173
Novel agent 180 (71) 76 (75) .565
Values are presented as mean ± SD or as n (%).
AF ¼ atrial ﬁbrillation; AFA¼ Arctic Front Advance; AFA-ST¼ Arctic Front Advance-Short Tip; CHADS2 ¼ congestive heart failure, hypertension, age ≥75 y,
diabetes, and stroke; LA ¼ left atrial.
*Signiﬁcant P value.
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ablation with eventual resolution before the end of procedure,
whereas persistent PN palsy was characterized by continued
loss of PN function that persisted during follow-up. If PN
palsy was encountered, the application was terminated and no
further ablation was performed using the cryoballoon.
Whenever the PVs could not be completely isolated using
cryoablation, point-by-point radiofrequency (RF) ablation
was used to achieve this acute end point. Furthermore,
arrhythmias other than AF (such as atrial ﬂutter/tachycardia)
were targeted using RF ablation. RF ablation was per-
formed using an externally irrigated ablation catheter
(ThermoCool SmartTouch, Biosense Webster, Inc.,
Diamond Bar, CA, or FlexAbility, St. Jude Medical, Inc.,
St. Paul, MN), guided by 3-dimensional electroanatomic
mapping (CARTO, Biosense Webster, Inc., or NavX,
St. Jude Medical, Inc.).
Postprocedural management
Patients were discharged from the hospital within 1 day of
the procedure. Oral anticoagulation was resumed on the
evening after the procedure and continued for a minimum of
3 months. Antiarrhythmic therapy was discontinued within 6
weeks of ablation. In addition to routine electrocardiograms
obtained during each follow-up visit, 2- to 4-week ambula-
tory electrocardiographic monitoring was performed at 6
weeks, 3 months, and 6 months. Freedom from recurrent
atrial arrhythmias was deﬁned as 430 seconds on anycardiac rhythm recording after a 90-day postablation
blanking period. In patients who opted for redo ablation,
repeat computed tomographic angiography was performed to
exclude PV stenosis. In those with persistent or unexplained
pulmonary symptoms (eg, persistent cough or dyspnea),
cardiac computed tomographic angiography was also
performed. Patients with persistent PN palsy underwent
outpatient serial chest x-ray imaging for reassessment during
follow-up.Statistical methods
Data are expressed as number (percentage) or mean ± SD.
Baseline patient demographic characteristics and procedural/
clinical characteristics were compared between the cohorts.
Continuous variables were analyzed using the 2-sample t test
or Mann-Whitney U test for parametric and nonparametric
variables, respectively. The χ2 or Fisher exact test was used
for categorical variables. Time to ﬁrst recurrence of atrial
arrhythmias was analyzed using Kaplan-Meier estimates,
and overall freedom from atrial arrhythmias was compared
between the 2 catheter groups using the log-rank test.
Point estimate comparisons at 10 months postindex
ablation were evaluated using a 2-sided Z test for difference.
For all analyses, P values were 2-sided and a P o .05
was considered statistically signiﬁcant. The analyses
were conducted with use of Stata 14 (StataCorp LP,
College Station, TX), SAS version 9.4 (SAS Institute, Inc.,
2309Aryana et al Cryoablation of AF Using AFA vs AFA-STCary, NC), and R statistical package version 3.2.2 (www.
r-project.org).Results
Altogether, data from 355 consecutive patients (72% with
paroxysmal AF) who underwent a ﬁrst-time Cryo-AF using
the AFA-ST (n ¼ 102) and the AFA (n ¼ 253) cryoballoons
were analyzed. Baseline patient demographic characteristics
were similar (Table 1). In total, 407 PVs (4.0 ± 0.3 PVs per
patient) were targeted using the AFA-ST and 1009 PVs (4.0
± 0.3 PVs per patient) using the AFA cryoballoon. The 28-
mm cryoballoon was used in nearly all cases (99.7%)
(Table 2). Acute isolation was achieved in 99.6% of all
PVs, and its frequency was similar between the AFA-ST and
the AFA cryoballoons (100% vs 99.4%; P ¼ .920). As such,
RF ablation was required to complete isolation of 6 of 1009
PVs (0.6%) in 4 of 253 patients (1.6%) using AFA, but none
using AFA-ST. TT-PVI was recorded in 89.2% of PVs using
AFA-ST as compared with only 60.2% using AFA (P o
.001). As a result, PVs isolated using AFA-ST required
fewer total and effective cryoapplications, but were associ-
ated with a higher rate of abandoned cryoapplications
(applications unable to achieve optimal TT-PVI as deﬁned
by this study’s prespeciﬁed protocol) (Table 2). AFA-ST was
also accompanied by shorter LA dwell time and total
procedure time, but with similar ﬂuoroscopic utilization.
Furthermore, in 28 patients (27.4%) ablated using AFA-ST,
the procedure was successfully completed by “single-shot”Table 2 Procedural characteristics and adverse events
Characteristic or outcome AFA (n ¼
Cryoballoon used
23-mm 1 (0.
28-mm 252 (99
PVs isolated 1003 (99
Ablation variables
TT-PVI (s) 47 ± 1
Total number of cryoapplications per PV 1.7 ± 0
No. of effective cryoapplications per PV 1.5 ± 0
No. of abandoned cryoapplications per PV 0.2 ± 0
Cryoapplication duration (s) 149 ± 3
Balloon nadir temperature (°C) −47.5 ± 7
Balloon thaw time (s) 44 ± 2
Total cryoablation time (min) 17 ± 5
RF ablation of atrial ﬂutter/tachycardia 36 (14
Total RF ablation time (min) 10 ± 7
Procedural variables
LA dwell time (min) 53 ± 1
Fluoroscopy time (min) 13 ± 5
Total procedure time (min) 89 ± 2
PN palsy
Transient 7 (2.
Persistent 2 (0.
Other adverse events 4 (1.
Groin complication 3 (1.
Pericardial effusion 1 (0.
Values are presented as mean ± SD or as n (%).
AFA ¼ Arctic Front Advance; AFA-ST¼ Arctic Front Advance-Short Tip; LA ¼ lef
PVI ¼ time to pulmonary vein isolation.
*Signiﬁcant P value.PV ablation (single cryoapplication per PV in all the PVs) as
opposed to 51 patients (20.2%) targeted using AFA (P ¼
.031). In addition, the frequency of recording TT-PVI in a
single PV per patient (97% vs 83%; Po .001), in 2 PVs per
patient (88% vs 62%; P o .001), and in 3 PVs per patient
(64% vs 40%; P o .001) was greater using AFA-ST than
using AFA (Figure 2). While there was a trend toward
improved recording of TT-PVI in all PVs per patient (34% vs
25%; P ¼ .072), this did not reach statistical signiﬁcance.
Conversely, there were no discernible differences in the
duration of TT-PVI, the duration of cryoapplications, bal-
loon nadir temperature, or balloon thaw times between the 2
cryoballoons (Table 2). Moreover, total cryoablation time
was similar between the 2 groups, as was the incidence of
atrial ﬂutters/tachycardias requiring RF ablation as well as
RF duration. PN palsy and procedure-related adverse events
were similar between the 2 groups. Furthermore, all patients
with transient/persistent PN palsy exhibited complete PVI.
The incidences of cardiac tamponade, stroke, atrioesophageal
ﬁstula, and death were zero during follow-up. Details about
procedural and biophysical variables associated with AFA and
AFA-ST cryoballoons by PV type are given in Table 3.
The mean follow-up period in this study was 12 ± 2
months, including 10 ± 1 months for AFA-ST and 13 ± 2
months for AFA. As illustrated in Figure 3, freedom from
recurrent atrial arrhythmias did not differ when compared
using the log-rank test (P ¼ .624). Furthermore, a 2-sided
Z test for differences at 10 months postindex ablation
demonstrated no statistical difference between the cohorts253) AFA-ST (n ¼ 102) P
4) 0 (0.0) .713
.6) 102 (100.0) .713
.4) 407 (100.0) .920
6 48 ± 17 .196
.8 1.6 ± 0.8 .023*
.3 1.3 ± 0.3 .034*
.1 0.3 ± 0.1 .034*
4 150 ± 35 .382
.8 −47.0 ± 7.3 .120
8 41 ± 24 .056
16 ± 4 .224
) 17 (17) .140
10 ± 11 .710
6 43 ± 5 o.001*
12 ± 6 .236
5 71 ± 11 o.001*
8) 2 (2.0) .736
8) 0 (0.0) .507
6) 1 (1.0) .554
2) 0 (0.0) .361
4) 1 (1.0) .493
t atrial; PN ¼ phrenic nerve; PV¼ pulmonary vein; RF ¼ radiofrequency; TT-
Figure 2 Assessment of TT-PVI by the number of PVs per patient. The frequency of recording TT-PVI in 1 PV per patient (97% vs 83%; Po .001), in 2 PVs
per patient (88% vs 62%; Po .001), and in 3 PVs per patient (64% vs 40%; Po .001) was greater using AFA-ST versus AFA. While there was a trend toward
improved recording of TT-PVI in all PVs per patient (34% vs 25%; P ¼ .072), this did not reach statistical signiﬁcance. AFA ¼ Arctic Front Advance;
AFA-ST ¼ Arctic Front Advance-Short Tip; PV ¼ pulmonary vein; TT-PVI ¼ time to pulmonary vein isolation.
Table 3 Comparisons of procedural and biophysical variables by PV type between the 2 groups
Variable AFA (n ¼ 1009) AFA-ST (n ¼ 407) P
Left common PV 19/20 (95.0) 5/5 (100.0) .627
Cryoapplication duration (s) 157 ± 38 153 ± 36 .782
TT-PVI (s) 56 ± 25 61 ± 7 .797
Nadir balloon temperature (°C) −41 ± 8 −40 ± 6 .832
Balloon thaw time (s) 18 ± 7 18 ± 6 .785
Left superior PV 233/233 (100.0) 97/97 (100.0) 1.000
Cryoapplication duration (s) 147 ± 34 154 ± 31 .057
TT-PVI (s) 46 ± 17 50 ± 17 .078
Nadir balloon temperature (°C) −46 ± 8 −46 ± 14 .549
Balloon thaw time (s) 43 ± 25 39 ± 21 .227
Left inferior PV 232/233 (99.6) 97/97 (100.0) .521
Cryoapplication duration (s) 151 ± 32 156 ± 31 .176
TT-PVI (s) 49 ± 14 51 ± 16 .208
Nadir balloon temperature (°C) −49 ± 8 −48 ± 8 .062
Balloon thaw time (s) 53 ± 32 48 ± 28 .238
Right superior PV 253/253 (100.0) 102/102 (100.0) 1.000
Cryoapplication duration (s) 150 ± 31 151 ± 32 .826
TT-PVI (s) 45 ± 15 46 ± 15 .569
Nadir balloon temperature (°C) −48 ± 8 −48 ± 7 .644
Balloon thaw time (s) 46 ± 27 43 ± 26 .526
Right middle PV 17/17 (100.0) 4/4 (100.0) 1.000
Cryoapplication duration (s) 145 ± 33 167 ± 19 .172
TT-PVI (s) 35 ± 19 36 ± 19 .923
Nadir balloon temperature (°C) −44 ± 8 −51 ± 9 .145
Balloon thaw time (s) 22 ± 18 45 ± 18 .053
Right inferior PV 249/253 (98.4) 102/102 (100.0) .195
Cryoapplication duration (s) 150 ± 32 153 ± 32 .487
TT-PVI (s) 49 ± 16 52 ± 18 .168
Nadir balloon temperature (°C) −46 ± 8 −46 ± 7 .970
Balloon thaw time (s) 38 ± 26 33 ± 23 .172
Values are presented as mean ± SD or as n/N (%).
AFA ¼ Arctic Front Advance; AFA-ST ¼ Arctic Front Advance-Short Tip; PV ¼ pulmonary vein; TT-PVI ¼ time to pulmonary vein isolation.
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Figure 3 Cumulative freedom from recurrent atrial arrhythmias after
cryoballoon ablation of atrial ﬁbrillation. A Kaplan-Meier curve illustrating
the cumulative freedom from recurrent atrial arrhythmias after cryoablation
using the AFA vs the AFA-ST cryoballoons, including the number of
patients at risk. AFA ¼ Arctic Front Advance; AFA-ST ¼ Arctic Front
Advance-Short Tip.
2311Aryana et al Cryoablation of AF Using AFA vs AFA-ST(AFA-ST: 81.8% freedom from atrial arrhythmias [95% CI
73.9–89.7] vs AFA: 79.9% freedom from atrial arrhythmias
[95% CI 74.7–84.7]; P ¼ .658).
In order to evaluate for any potential “learning curve”
inﬂuences on the data sets, the AFA and AFA-ST cohorts
were reexamined after dividing each group into 2 equal
halves on the basis of the procedure timelines. When
comparing the initial (ﬁrst-half) phase with the latter
(second-half) phase of the AFA cohort, ﬂuoroscopy duration
(13 ± 5 minutes vs 13 ± 6 minutes; P¼ .639), LA dwell time
(54 ± 12 minutes vs 52 ± 18 minutes LA; P ¼ .360), and
“single-shot” PV ablation (15.1% vs 25.4%; P ¼ .060) did
not signiﬁcantly differ. Only procedure time was shorter
during the latter phase in the AFA arm (92 ± 26 minutes vs
85 ± 23 minutes; P ¼ .021). Similarly, in the AFA-ST arm,
when comparing the initial phase with the latter phase of the
study, procedure time (70 ± 12 minutes vs 72 ± 12 minutes;
P¼ .303), LA dwell time (43 ± 5 minutes vs 43 ± 5 minutes;
P ¼ .796), and “single-shot” PV ablation (35.3% vs 19.6%;
P ¼ .120) did not statistically differ. However, ﬂuoroscopic
utilization was slightly longer in the AFA-ST arm during the
latter phase of the study (11 ± 5 minutes vs 14 ± 7 minutes;
P ¼ .034).
Four patients (3.9%) ablated using AFA-ST and 18
patients (7.1%) ablated using AFA underwent a redo
procedure because of recurrent symptomatic atrial arrhyth-
mias, and all were deemed as clinical efﬁcacy failures in this
study analysis. In 3 patients treated with AFA-ST (75%), all
PVs were found to be electrically isolated during the redo
procedure. One patient exhibited reconnection of the right
inferior PV, which was reablated. In the AFA arm, 15 of 18
patients (83%) exhibited durable isolation of all PVs during
the redo procedure. The remaining 3 patients each exhibitedsingle PV reconnection, which were also reisolated. Of these,
2 patients had developed reconnection of the right inferior PV,
and 1 patient exhibited reconnection of the left inferior PV.Discussion
This analysis represents the ﬁrst, large multicenter report on
the short- and long-term safety and efﬁcacy outcomes of
Cryo-AF using the novel third-generation AFA-ST cryobal-
loon. As such, it provides several pertinent insights. First, it
shows that TT-PVI during Cryo-AF can be recorded more
readily using AFA-ST as compared with its second-gener-
ation predecessor. Consequently, effective PVI using AFA-
ST was consistently attained by means of fewer cryoappli-
cations. Second, AFA-ST allowed more frequent procedural
completion through “single-shot” PV ablation, without
compromising clinical efﬁcacy. Third, both LA dwell time
and total procedure time were considerably reduced. Lastly,
freedom from recurrent atrial arrhythmias was similar
between the 2 balloons during long-term follow-up.
Cryo-AF has emerged as a practical and effective strategy
for the treatment of AF.10 Nonetheless, the optimal cryoa-
blation dosing still remains unclear. Several studies have
established the utility of monitoring TT-PVI using an inner
lumen circular mapping catheter. Chierchia et al5 illustrated
that early PV reconnection was associated with a signiﬁ-
cantly longer TT-PVI (117 ± 25 seconds vs 59± 25 seconds)
as recorded using this approach. Similarly, Chun et al6
showed that a TT-PVI associated with durable PVI was
signiﬁcantly shorter than in those with electrical reconnec-
tion (66 ± 56 seconds vs 129 ± 76 seconds). Kühne et al7
further corroborated these ﬁndings by identifying a mean
TT-PVI of 61 seconds in PVs exhibiting permanent isolation
as compared with 184 seconds in those with conduction
recovery. More recently, a multicenter analysis has estab-
lished that among the various procedural and biophysical
variables of Cryo-AF, a TT-PVI of ≤60 seconds represents
the best indicator of durable PVI during long-term follow-
up.4
Meanwhile, in most studies as well as in clinical practice
TT-PVI cannot always be consistently measured. This has in
part been a reﬂection of the design of the AFA cryoballoon.
Speciﬁcally, the prolonged distal tip of AFA can frequently
physically impede sufﬁcient withdrawal of the inner lumen
circular mapping catheter to a proximal position within the
PV ostia. Since the PV muscular sleeves typically occupy
only the proximal segments of the PVs, this catheter design
can often hinder the ability to routinely assess TT-PVI.9 In
fact, in most studies the ability to reliably assess TT-PVI
using the circular mapping and AFA catheters is reported in
only ~50% of the PVs.5–7,9 However, recent design mod-
iﬁcations have led to the development of the AFA-ST
balloon that exhibits a much shorter distal tip (Figure 1).
Two recent single-center studies11,12 have demonstrated
higher rates of real-time electrical PV recordings using the
AFA-ST cryoballoon. As illustrated in the present study, this
design adjustment not only enhanced the ability to record PV
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also improved the procedural efﬁciency by minimizing the
number of total and effective cryoapplications, LA dwell
time, and total procedure time. In essence, AFA-ST
enhanced the frequency of “electrogram-guided” vs
“empiric” cryoapplications. Ultimately, this translated into
a higher rate of procedural completion by “single-shot” PV
ablation while still maintaining clinical efﬁcacy. In contrast,
total cryoablation time was similar when comparing the 2
balloons. That is, the time gained from fewer effective
cryoapplications needed to achieve PVI using AFA-ST
was partially offset by a higher incidence of abandoned
cryoapplications needed to optimally achieve this end point.
As such, AFA-ST maximized the delivery of effective
cryoapplications, whereas ablation using AFA depended to
a greater extent on “empiric” ablation and driven less by PV
electrograms or PVI. Moreover, the biophysical character-
istics of the AFA-ST catheter appear strikingly similar to
those of the AFA balloon.
The improved biophysical properties and superior efﬁ-
cacy associated with the AFA balloon over the ﬁrst-
generation cryoballoon (Arctic Front. Medtronic, Inc.) has
been well-described.13,14 This is thought to be related to the
increased number and location of the refrigerant injection
ports incorporated into the AFA balloon, which, in turn,
results in the expansion of the maximal cooling zone beyond
this balloon’s equator to the entire distal half of its surface
and including the distal tip. Even though there are subtle
differences in the internal design of AFA-ST and AFA, it is
reassuring to note that the biophysical behaviors of these 2
ablation catheters are essentially similar. Likewise, the
adverse event rates including that of PN palsy were
equivalent between AFA-ST and AFA balloons. Moreover,
in spite of its much shorter distal tip there were no discernible
catheter/balloon stability issues concerning the AFA-ST
balloon reported by any of the operators in this study.
Although in their study, Heeger et al11 found slightly higher
nadir temperatures associated with the AFA-ST balloon
(presumably because of a more proximal displacement of
the thermocouple on AFA-ST than on AFA), this was not
evident in the present study. In fact, we found no signiﬁcant
differences in balloon nadir temperature, duration of TT-
PVI, or balloon thaw times associated with the 2 balloon
catheters. This is not surprising since the absolute cryobal-
loon nadir temperature is subject to considerable variation as
a consequence of a multitude of dependent and independent
variables such as the size of the cryoballoon used (23-mm vs
28-mm, with the latter exhibiting 50% greater surface area),
the balloon position within the PV ostia (proximal vs distal),
balloon to PV diameter ratio, ipsilateral PV blood ﬂow, and
even subtle manipulations by the operator. Thus, as one
would expect, balloon nadir temperature by itself has also
been shown to serve as only a weak indicator of long-term
procedural efﬁcacy and PVI durability.4
In summary, the main ﬁndings of this analysis suggest
that AFA-ST is superior to its second-generation predecessor
by providing an improved ability to record PV electrogramsand assessing TT-PVI. This was, in turn, accompanied by
inherent procedural efﬁciencies, including fewer total and
effective cryoapplications and shorter LA dwell time and
total procedure time. Furthermore, it enhanced the ability
to complete Cryo-AF using a “single-shot” technique,
without compromising safety or procedural and clinical
efﬁcacy. However, it needs to be emphasized that although
AFA-ST offers an improved ability to assess TT-PVI, this
by itself is insufﬁcient to guarantee a successful outcome.
As such, the operator must still follow and use the
procedural and biophysical indicators necessary to achieve
effective PVI.4Study limitations
First, this study represents a large, nonrandomized, double-
arm analysis of consecutive patients undergoing Cryo-AF
using the AFA or the AFA-ST cryoballoons. As such, since
the treatment allocation was nonrandomized, we cannot
exclude unknown characteristics that may have confounded
either treatment arm. Second, since this was a multicenter
study, slight variations in ablation strategy and periproce-
dural management and monitoring may have existed among
operators and centers. Third, subclinical manifestation of
certain complications such as esophageal ulceration or PV
stenosis could not be excluded, since routine diagnostic
studies were not performed to investigate such adverse
events. Fourth, the data presented on PV reconnection
pertains only to those who underwent repeat ablation and
was unavailable for the entire cohort. Fifth, the authors
cannot exclude the possibility of temporal bias. That is, in the
initial period of the study, all Cryo-AF cases were consec-
utively performed using the AFA balloon whereas all the
cases in the second part of the study were performed using
the AFA-ST balloon. Furthermore, recurrent asymptomatic
episodes of atrial arrhythmias after Cryo-AF could have
occurred without detection during follow-up. However, it
would seem unlikely that this would have served as a
signiﬁcant source of bias speciﬁcally favoring one or the
other treatment arm. Lastly, it should be emphasized that
although AFA-ST appears to represent an improved tool for
the assessment of TT-PVI, this alone is insufﬁcient to ensure
effective PVI. Moreover, the observed beneﬁts associated
with AFA-ST were all related to procedural outcomes and
not arrhythmia recurrence.Conclusion
Cryo-AF using the newly available AFA-ST offers an
enhanced ability to record TT-PVI as compared with its
second-generation predecessor. This allowed for fewer total
and effective cryoapplications and shorter LA dwell time
and total procedure time. Furthermore, with the use of this
novel balloon, Cryo-AF could be completed more fre-
quently by means of “single-shot” PV ablation while
maintaining equivalent procedural safety and clinical
efﬁcacy.
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